BIOTECH ASSISTANT / FIELD NOTES

Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice

Academic source · Molecular Therapy

Source published: 2026-07-29

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

A Coxsackievirus B5 replicon used internal ribosome entry site-driven translation to generate a capless self-amplifying RNA vaccine. Genetic optimization improved expression, and LNP-formulated H5 antigen constructs induced neutralizing antibodies and cellular responses in mice. Low-dose vaccination protected against lethal H5N8 challenge. The platform changes capping requirements, but human immunogenicity, manufacturing performance, and safety remain unestablished.

Why this paper is included

Introduces a cap-independent saRNA architecture with mouse dose-sparing evidence; clinical dosing and process advantages have not yet been demonstrated.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP

Related updates

2026-11-06Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNP Ask AI ↗

2026-11-05Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

mRNA / LNP Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-04Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.